Milestone Pharmaceuticals Announces $25 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Milestone Pharmaceuticals (MIST) PT Doubled to $12 at Cowen
July 23, 2020 3:43 PM EDTCowen analyst Ritu Baral raised the price target on Milestone Pharmaceuticals (NASDAQ: MIST) to $12.00 (from $6.00) while maintaining an Outperform rating.
The analyst commented, "MIST announced etrepamil's path forward agreed upon with FDA which allows amending the NODE-301 trial stat plan for... More
Milestone Pharmaceuticals Inc. (MIST) Surges 70% on Updated Clinical Development Plan for Etripamil in PSVT
July 23, 2020 8:06 AM EDTMilestone Pharmaceuticals Inc. (NASDAQ: MIST) surges 70% after the company announced a clinical and regulatory update... More
Milestone Pharmaceuticals Inc. (MIST) Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
July 23, 2020 7:15 AM EDTMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced a clinical and regulatory update for its pivotal program with etripamil following recent interactions with the U.S. Food and Drug Administration (FDA). Etripamil nasal spray is the Company's investigational novel short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia (PSVT).
"We are pleased with the outcome of our recent interactions with the FDA, as they outline an efficient path to registration for etripamil which eliminates the need to start a... More
